Breaking News

CDC Confirms First Ebola Case Diagnosed in the United States
Tweet TWEET

ACADIA Pharmaceuticals Prices Public Offering of Common Stock

  ACADIA Pharmaceuticals Prices Public Offering of Common Stock

Business Wire

SAN DIEGO -- May 15, 2013

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the pricing of an
underwritten public offering of 8,000,000 shares of its common stock, offered
at a price to the public of $12.50 per share. The gross proceeds from this
offering to ACADIA are expected to be $100 million, before deducting
underwriting discounts and commissions and other estimated offering expenses
payable by ACADIA. ACADIA has granted the underwriters a 30-day option to
purchase up to an aggregate of 1,200,000 shares of common stock to cover
over-allotments, if any. The offering is expected to close on or about May 20,
2013, subject to customary closing conditions. ACADIA expects to use net
proceeds of this offering to fund ongoing and new clinical trials and
development and commercialization efforts for pimavanserin and its other
product candidates and for general corporate purposes, which may include
research, development and commercialization expenses, capital expenditures,
working capital, and general and administrative expenses.

Jefferies LLC and Cowen and Company, LLC are acting as the joint book-running
managers for the offering. JMP Securities LLC, Needham & Company, LLC,
Ladenburg Thalmann & Co. Inc., Roth Capital Partners, LLC, and SunTrust
Robinson Humphrey, Inc. are acting as co-managers for the offering.

The shares of common stock described above are being offered by ACADIA
pursuant to a shelf registration statement previously filed by ACADIA with the
Securities and Exchange Commission (SEC) and declared effective by the SEC on
January 6, 2012. A preliminary prospectus supplement related to the offering
was filed with the SEC and is available on the SEC's website located at
http://www.sec.gov. Copies of the final prospectus supplement and the
accompanying prospectus relating to this offering, when available, may be
obtained from Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520
Madison Avenue, 12th floor, New York, NY 10022 or by telephone at 877-547-6340
or by email at Prospectus_Department@Jefferies.com, or from Cowen and Company,
LLC (c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY,
11717, Attn:Prospectus Department, Phone: 631-274-2806, Fax: 631-254-7140).

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
jurisdiction.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on innovative treatments that
address unmet medical needs in neurological and related central nervous system
disorders. ACADIA has a pipeline of product candidates led by pimavanserin,
which is in Phase III development as a treatment for Parkinson's disease
psychosis. ACADIA also has clinical-stage programs for chronic pain and
glaucoma in collaboration with Allergan, Inc. and two advanced preclinical
programs directed at Parkinson’s disease and other neurological disorders. All
product candidates are small molecules that emanate from discoveries made at
ACADIA.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature
are forward-looking statements. These statements include but are not limited
to statements related to expectations regarding the completion, timing and
size of the offering of common stock by ACADIA, the expected gross and net
proceeds from the offering and ACADIA’s expected use of the net proceeds from
the offering. These statements are only predictions based on current
information and expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected in any of
such statements due to various factors, including market risks and
uncertainties and the satisfaction of customary closing conditions for an
offering of securities. For a discussion of these and other factors, please
refer to ACADIA’s annual report on Form 10-K for the year ended December31,
2012 as well as ACADIA’s subsequent filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. This
caution is made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. All forward-looking statements are qualified in
their entirety by this cautionary statement and ACADIA undertakes no
obligation to revise or update this press release to reflect events or
circumstances after the date hereof, except as required by law.

Contact:

ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, Executive Vice President,
Chief Financial Officer and Chief Business Officer
Lisa Barthelemy, Director of Investor Relations
(858) 558-2871
 
Press spacebar to pause and continue. Press esc to stop.